Basel, 24 Sept 2009 Alternative methods to reduce the use of animals in research rewarded Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit the use of animals in preclinical research - to recognise and reward innovation and continuous improvement in animal welfare within the Roche research organisation. The award, which is now in its second year, is based on the 3Rs concept, which means Replacing animal tests where possible, Reducing the number of animals required and Refining existing scientific practices as well as animal care and husbandry. Fifteen teams of Roche scientists and animal care specialists from the companies’ global research sites in Basel, Penzberg, Nutley and Tokyo applied for awards in two categories: “Scientific Progress Fostering the 3Rs Idea” and “Laboratory Animal Care and Management”.

In the Scientific category, a joint Basel-Penzberg Team received the award for improved cellular readouts which allow sensitive detection of drug candidate liabilities before entering animal testing. The team found a new in vitro assay that identifies toxic compounds early on without testing them on laboratory animals. This will also help to improve attrition rates in drug research.

The winner in the second category is a team animal care specialists from Basel. Their project involved gradually moving animals that were individually housed into pairs, then into smaller groups and finally into larger collectives. These housing changes increased the animals’ social interaction and improved their overall well-being.

The global 3Rs Award program aims to strengthen Roche’s commitment by rewarding innovation, fostering continuous improvement, encouraging global idea sharing across the organization, and challenging Roche researchers around the world to think of new ways to implement the 3Rs. Wide participation in the 3Rs Award program proves that Roche scientists are steadfastly dedicated to the tenets of the 3Rs and unwavering in their quest to find ways replace and reduce the use of animals. The award also raises awareness of Roche’s continued commitment and responsibility to animal welfare.

While the number of animals used in research has declined over years, researchers still depend on them to gain critical scientific knowledge for novel medicines and to predict the effectiveness and side effects of medicines in humans. About 70 percent of serious side effects of new medicines are only predictable through animal testing.

More on the 3Rs

First described in 1959 by two English scientists, Russell and Burch, the 3Rs concept means Replacing animal tests where possible, Reducing the number of animals required and Refining existing scientific practices while still maintaining comparable results. Although the 3Rs were introduced 50 years ago, the concept continues to provide global companies with guidance on alternative approaches to animal testing in research. Scientists should ask three questions about every experiment: Do animals need to be used all? Can fewer animals be used? Can tests be conducted in such a way that they do not cause distress and pain to the animals? Abiding by the 3Rs helps to ensure that animals are only used when they are indispensable to gain critical scientific knowledge to develop future medicines.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80’000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.